Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...
Drug
Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment
The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...
Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...
Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment
Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...
Staidson Receives NMPA Approval for Clinical Trial of STSA-1301 in Primary Immune Thrombocytopenia
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...
Allist Pharmaceuticals’ Furmonertinib Receives FDA Breakthrough Therapy Designation for NSCLC
Shanghai-based biotech Allist Pharmaceuticals Co., Ltd (SHA: 688578) has announced that it has received breakthrough...
Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US
Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I...
CDE Grants Priority Review to LaNova’s LM-302, Roche’s Alectinib, and Alphamab’s KN026
China’s Center for Drug Evaluation (CDE) has indicated that LaNova Medicines’ LM-302, Roche’s (SWX: ROG)...
Boan Biotech Enrolls First Patient in Phase III Study for Opdivo Biosimilar BA1104 in China
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced the enrollment of...
CSPC Pharmaceutical Group Gains NMPA Approval for Bivalent COVID-19 mRNA Vaccine Study
CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent pharmaceutical company based in China, has announced...
GenFleet Therapeutics’ SLS009 Receives FDA Fast-Track Status for PTCL Treatment
Shanghai-based biotech GenFleet Therapeutics has announced that its investigational drug SLS009 (GFH009) has received fast-track...
CStone Pharmaceuticals Receives NMPA Approval for Sugemalimab in R/R ENKTL
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received a...
Simcere Pharmaceutical Group Secures Full Approval for Cosela in China
Simcere Pharmaceutical Group (HKG: 2096), a leading pharmaceutical company based in China, has announced that...
Novartis Announces Positive Interim Results for Atrasentan in IgA Nephropathy Phase III Study
Novartis (NYSE: NVS), a global healthcare company, has released interim results from an ongoing Phase...
Roche’s Vabysmo Receives FDA Approval for Macular Edema Treatment Following RVO
Swiss pharmaceutical giant Roche (SWX: ROG) announced last week that it has received an indication...
Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial
Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...
China Grand Pharma’s Lava Liquid Embolic Agent Officially Commercialized in the US
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the official commercialization...
Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...